Connect with us

Business

Karyopharm Therapeutics Grants Restricted Stock Units to New Employees

Published

2 weeks ago

on

Karyopharm Therapeutics Office

NEWTON, Mass., Sept. 3, 2024 / / — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a pharmaceutical company focused on developing innovative cancer therapies, has announced the granting of a total of 22,050 restricted stock units (RSUs) to five newly hired employees.

The RSU awards were granted as of August 31, 2024, as part of the company’s 2022 Inducement Stock Incentive Plan. This action aligns with Nasdaq Listing Rule 5635(c)(4), which allows companies to award stock options or RSUs as an inducement for new employees to join the organization.

Each RSU granted will vest over a period of three years. Specifically, one-third of the shares underlying each RSU award will become vested on each of the consecutive anniversaries of the Grant Date. Vesting is conditional upon the employees maintaining their service with Karyopharm during this period.

Furthermore, the RSUs will be fully exercisable if, within the first year following a change in control event, the employee’s contract is terminated for “good reason” by the employee or without “cause” by Karyopharm, in accordance with the definitions set forth in the respective RSU agreements.

Rachel Adams

Times News Global is a dynamic online news portal dedicated to providing comprehensive and up-to-date news coverage across various domains including politics, business, entertainment, sports, security, features, opinions, environment, education, technology and global. affairs. Our commitment lies in sharing news that is based on factual accuracy, credibility, verifiability, authority and depth of research. We pride ourselves on being a distinctive media organization, guided by the principles enshrined in Article 19 of the Universal Declaration of Human Rights. Made up of a team of ordinary people driven by an unwavering dedication to uncovering the truth, we publish news without bias or intimidation.